RDIF invites foreign scientists to join real-world studies of Sputnik vaccines

Interfax, 07.10.2021

MOSCOW. Oct 7 (Interfax) - The Russian Direct Investment Fund (RDIF) has urged foreign experts to take part in studies on the efficacy and safety of the Russian-designed Sputnik V coronavirus vaccine based on the results of earlier vaccination campaigns among the population.

"Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) is inviting independent international researchers and scientific institutions to cooperate on real-world studies of safety and efficacy of coronavirus vaccines, including Sputnik V, Sputnik Light, and other," the RDIF said in a statement on its website on Thursday.

The key topics for cooperation proposed by the RDIF include "real-world studies" on the safety and efficacy of Sputnik V and Sputnik Light, "efficacy factor analysis," comparative analysis of real-world data on the safety and efficacy of Sputnik V, Sputnik Light, and other vaccines, as well as of real-world data on Sputnik Light's safety and efficacy as a booster, it said.

Anyone interested in engaging in this joint work is invited to send their proposals to the RDIF.

"The Fund is interested in expanding the knowledge of Russian and international scientists, as well as raising public awareness regarding the real-world data on safety and efficacy of Sputnik V, Sputnik Light, and other vaccines," the RDIF said.